Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VII. Ketamine
Viviana D. Evans, Alejandro Arenas, Kenneth Shinozuka et al. preprint
Background: Ketamine, an arylcyclohexylamine dissociative anesthetic agent, has evolved into a versatile therapeutic. It has a rapid onset, well-understood cardiovascular effects, and a favorable safety profile in clinical use. Its enantiomeric compound, esketamine, was approved by the FDA in 2019 for both treatment-resistant depression as well as major depressive disorder (MDD) with suicidal...